Vadadustat, sold under the brand name Vafseo is a

medication A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy ( pharmacotherapy) is an important part of the medical field and ...

used for the treatment of symptomatic

anemia Anemia or anaemia (British English) is a blood disorder in which the blood has a reduced ability to carry oxygen due to a lower than normal number of red blood cells, or a reduction in the amount of hemoglobin. When anemia comes on slowly, t ...

associated with chronic kidney disease. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. The most common side effects include thromboembolic events (problems due to the formation of blood clots in the blood vessels),

diarrhea Diarrhea, also spelled diarrhoea, is the condition of having at least three loose, liquid, or watery bowel movements each day. It often lasts for a few days and can result in dehydration due to fluid loss. Signs of dehydration often begin w ...

, and hypertension (high blood pressure). Vadadustat was approved for medical use in the European Union in April 2023.

Medical uses

Vadadustat is

indicated In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...

for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.

Society and culture

Legal status

On 23 February 2023, the

Committee for Medicinal Products for Human Use The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regardin ...

(CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vafseo, intended for the treatment of symptomatic anemia in adults with chronic kidney disease who are on chronic dialysis. The applicant for this medicinal product is Akebia Europe Limited. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Vadadustat was approved for medical use in the European Union in April 2023.

Research

Vadadustat is in phase III clinical trials for the treatment of

caused by chronic kidney disease.

References

Acetic acids Pyridines {{Blood-drug-stub